Pharma Focus Asia
KP - Choose our fully recyclable blister films

Loxo@Lilly Discovered Novel Jaypirca™ (pirtobrutinib) for Adult Patients

Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor.

Jaypirca, a highly selective kinase inhibitor, which uses a novel binding mechanism. Jaypirca has the ability to restore BTK inhibition in MCL in patients who have earlier treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib) and extend the benefit of targeting the BTK pathway. Jaypirca will beocme the new treatment option and brings new hope for people with relapsed or refractory MCL.

Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300-fold selective for BTK compared to 98% of other kinases tested in preclinical studies), non-covalent (reversible) enzyme. Jaypirca is an oral prescription drug approved as 100 mg or 50 mg tablets taken once daily. 200 mg  with or without food until disease progression or toxicity is unacceptable.

U.S. Food and Drug Administration (FDA) approves Jaypirca™ for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024